Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024

INCYTE CORP

2023-FY EPS reported $2.65 revenue$3,695,649,000

Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.
Jakafi FY23 net product revenue $2.59B (+8%); 2024 Jakafi guidance $2.69-$2.75B.
Opzelura FY23 net product revenue $338M (+162%) driven by atopic dermatitis and vitiligo launch.
GAAP FY23 net income $598M (diluted EPS $2.65); Non-GAAP net income $795M (diluted EPS $3.52).
Acquired worldwide rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys for $25M upfront.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INCYTE CORP updated its fourth fiscal quarter and year ended December 31, 2023 guidance (initiated).

Period: fourth fiscal quarter and year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0000879169-24-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.